{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:01:47Z","timestamp":1784602907008,"version":"3.55.0"},"reference-count":48,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background: Although, in most children with asthma, good symptom control is achieved with a low to moderate dose of inhaled corticosteroids, a small group of patients still experiences frequent symptoms, and even severe exacerbations, impairment of lung function, and reduced quality of life. Some of these subjects with severe asthma require biologic drugs as add-on therapy. In the past decade, numerous monoclonal antibodies have been approved for children or adolescents with severe asthma, in addition to their increasing use in adult asthma. However, the available evidence on how to select the most appropriate biologic based on a single patient\u2019s clinical, functional, and laboratory characteristics is still scant, and is insufficient to guide clinicians in the decision-making process of a personalized treatment. Materials and Methods: We report a case series of four patients with severe eosinophilic asthma treated with mepolizumab, an anti-interleukin-5 monoclonal antibody, and review the existing literature on this treatment in children and adolescents. Results: Our patients, all with blood eosinophilia and elevated fractional exhaled nitric oxide levels, developed poor symptom control despite prolonged treatment with high-dose inhaled corticosteroids plus a second controller, addressing the addition of a biologic drug. In all of them, a 12-month treatment with subcutaneous mepolizumab showed a reduction in the blood eosinophil count and in asthma exacerbations, as well as an improvement on the Asthma Control Test. The results of the literature search focused on the strengths and limitations of the pediatric use of mepolizumab and highlighted the areas worthy of further research. Conclusions: Mepolizumab has proven effective in improving symptom control in pediatric patients with severe asthma. Additional well-powered clinical trials will be helpful in developing evidence-based guidelines regarding biologic drugs in the pediatric population.<\/jats:p>","DOI":"10.3390\/children11080895","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T11:43:44Z","timestamp":1721907824000},"page":"895","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mepolizumab in Severe Pediatric Asthma: Certainties and Doubts through a Single-Center Experience and Review of the Literature"],"prefix":"10.3390","volume":"11","author":[{"given":"Marco","family":"Maglione","sequence":"first","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy"},{"name":"Pediatric Emergency Unit, \u201cSantobono-Pausilipon\u201d Children\u2019s Hospital, 80129 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7282-6018","authenticated-orcid":false,"given":"Melissa","family":"Borrelli","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6414-5244","authenticated-orcid":false,"given":"Alessandro","family":"Dorato","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cimbalo","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Antonio","family":"del Giudice","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-7429","authenticated-orcid":false,"given":"Francesca","family":"Santamaria","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II University, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dharmage, S.C., Perret, J.L., and Custovic, A. (2019). Epidemiology of Asthma in Children and Adults. Front. Pediatr., 7.","DOI":"10.3389\/fped.2019.00246"},{"key":"ref_2","unstructured":"(2024, May 22). Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Updated May 2024. Available online: www.ginasthma.org."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2023.09.044","article-title":"Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma","volume":"154","author":"Bacharier","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.waojou.2023.100837","article-title":"Unanswered questions on the use of biologics in pediatric asthma","volume":"16","author":"Nieto","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI Biologicals Guidelines-Recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"ref_7","unstructured":"(2015, December 04). GSK\u2019s Nucala (Mepolizumab) Receives Approval from US FDA. Available online: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-s-nucala-mepolizumab-receives-approval-from-us-fda."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"00750","DOI":"10.1183\/23120541.00750-2023","article-title":"Efficacy and safety of mepolizumab in a Chinese population with severe asthma: A phase III, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Chen","year":"2024","journal-title":"ERJ Open Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): A randomised, double-blind, placebo-controlled, parallel-group trial","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): A randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial","volume":"18","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ppul.24508","article-title":"Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma","volume":"54","author":"Gupta","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/a-1717-2234","article-title":"Mepolizumab Treatment in Severe Pediatric Asthma: First Multicentric Real-World Data","volume":"234","author":"Wetzke","year":"2022","journal-title":"Klin. Padiatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/02770903.2024.2303767","article-title":"Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: A single Center experience","volume":"61","author":"Lim","year":"2024","journal-title":"J. Asthma"},{"key":"ref_17","unstructured":"(2024, June 29). SIGN 158 British Guideline on the Management of Asthma. A National Clinical Guideline BTS\/SIGN. Available online: https:\/\/www.sign.ac.uk\/our-guidelines\/british-guideline-on-the-management-of-asthma\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(23)00004-8","article-title":"Differing effects of mepolizumab across the life course","volume":"11","author":"Bush","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","volume":"144","author":"Gupta","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.15586\/aei.v49i5.466","article-title":"Steroid-sparing effect of mepolizumab in children with severe eosinophilic nonallergic asthma","volume":"49","author":"Tosca","year":"2021","journal-title":"Allergol. Immunopathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1901874","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: Typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/02770903.2019.1579833","article-title":"Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: One center\u2019s early clinical experience","volume":"57","author":"Weir","year":"2020","journal-title":"J. Asthma"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.jaci.2017.08.020","article-title":"TH1 signatures are present in the lower airways of children with severe asthma, regardless of allergic status","volume":"141","author":"Wisniewski","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MCP.0000000000000441","article-title":"Airway remodeling in asthma: Update on mechanisms and therapeutic approaches","volume":"24","author":"Boulet","year":"2018","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s40265-023-01905-5","article-title":"Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study","volume":"83","author":"Domingo","year":"2023","journal-title":"Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/02770903.2021.1903917","article-title":"Effect of omalizumab on bronchoalveolar lavage matrix metalloproteinases in severe allergic asthma","volume":"59","author":"Przybyszowski","year":"2022","journal-title":"J. Asthma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000334701","article-title":"Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma","volume":"83","author":"Hoshino","year":"2012","journal-title":"Respiration"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.anai.2014.06.004","article-title":"Comprehensive efficacy of omalizumab for severe refractory asthma: A time-series observational study","volume":"113","author":"Tajiri","year":"2014","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5603\/ARM.a2018.0046","article-title":"Influence of omalizumab therapy on airway remodeling assessed with high-resolution computed tomography (HRCT) in severe allergic asthma patients","volume":"86","author":"Przybyszowski","year":"2018","journal-title":"Adv. Respir. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI17974","article-title":"Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics","volume":"112","author":"Phipps","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Vantaggiato, L., Cameli, P., Bergantini, L., d\u2019Alessandro, M., Shaba, E., Carleo, A., Di Giuseppe, F., Angelucci, S., Sebastiani, G., and Dotta, F. (2022). Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment. Biomedicines, 10.","DOI":"10.3390\/biomedicines10040761"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tsuge, M., Ikeda, M., and Tsukahara, H. (2022). Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma. Children, 9.","DOI":"10.3390\/children9081253"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1573398X13666170616110738","article-title":"An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases","volume":"13","author":"Licari","year":"2017","journal-title":"Curr. Respir. Med. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1183\/09031936.00008115","article-title":"Real-life long-term omalizumab therapy in children with severe allergic asthma","volume":"46","author":"Deschildre","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ppul.26764","article-title":"Healthcare costs and resources utilization in children with difficult-to-control asthma treated with biologic therapies: A population-based cohort study","volume":"59","author":"Conflitti","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/02770903.2020.1837158","article-title":"Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore","volume":"59","author":"Tan","year":"2022","journal-title":"J. Asthma"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.vhri.2022.12.007","article-title":"Cost-Effectiveness of Mepolizumab Add-On in the Treatment of Severe Eosinophilic Asthma in Chile","volume":"35","author":"Abbott","year":"2023","journal-title":"Value Health Reg. Issues"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Chaogang, X., Mengna, A., Zhen, W., Ying, L., Xin, G., Xin, Z., Shengjie, Z., Yuan, Z., Qian, L., and Wenbin, M. (2024). Cost-effectiveness of mepolizumab for severe eosinophilic asthma in China. J. Asthma, 1\u20138.","DOI":"10.1080\/02770903.2024.2324855"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100509","DOI":"10.1016\/j.waojou.2021.100509","article-title":"Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life","volume":"14","author":"Bagnasco","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/jor2030010","article-title":"Use of Mepolizumab in Children and Adolescents with Asthma in the USA","volume":"2","author":"Davis","year":"2022","journal-title":"J. Respir."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5644\/ama2006-124.291","article-title":"Diagnosis and Management of Problematic Severe Asthma","volume":"49","author":"Scotney","year":"2020","journal-title":"Acta Med. Acad."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ullmann, N., Peri, F., Florio, O., Porcaro, F., Profeti, E., Onofri, A., and Cutrera, R. (2022). Severe Pediatric Asthma Therapy: Mepolizumab. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.920066"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00408-024-00670-w","article-title":"Predictors of Early and Late Lung Function Improvement in Severe Eosinophilic Asthma on Type2-Biologics in the PRISM Study","volume":"202","author":"Pham","year":"2024","journal-title":"Lung"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.15586\/aei.v51i5.877","article-title":"Time effect of dupilumab to treat severe uncontrolled asthma in adolescents: A pilot study","volume":"51","author":"Indolfi","year":"2023","journal-title":"Allergol. Immunopathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaci.2023.01.002","article-title":"Biologics in the treatment of asthma in children and adolescents","volume":"151","author":"Bacharier","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wilson, G.E., Knight, J., Liu, Q., Shelar, A., Stewart, E., Wang, X., Yan, X., Sanders, J., Visness, C., and Gill, M. (2024). Activated sputum eosinophils associated with exacerbations in children on mepolizumab. J. Allergy Clin. Immunol., in press.","DOI":"10.1016\/j.jaci.2024.01.031"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2213-2600(21)00275-7","article-title":"GINA 2021: The missing pieces in the childhood asthma puzzle","volume":"9","author":"Santamaria","year":"2021","journal-title":"Lancet Respir. Med."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/8\/895\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:23:13Z","timestamp":1760109793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/8\/895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["children11080895"],"URL":"https:\/\/doi.org\/10.3390\/children11080895","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]}}}